137 related articles for article (PubMed ID: 8106629)
1. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.
Greenman Y; Melmed S
J Clin Endocrinol Metab; 1994 Feb; 78(2):398-403. PubMed ID: 8106629
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
5. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
7. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.
Reubi JC; Schaer JC; Waser B; Mengod G
Cancer Res; 1994 Jul; 54(13):3455-9. PubMed ID: 8012966
[TBL] [Abstract][Full Text] [Related]
8. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
[TBL] [Abstract][Full Text] [Related]
9. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.
Greenman Y; Melmed S
J Clin Endocrinol Metab; 1994 Sep; 79(3):724-9. PubMed ID: 7521350
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
11. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
Panetta R; Patel YC
Life Sci; 1995; 56(5):333-42. PubMed ID: 7530798
[TBL] [Abstract][Full Text] [Related]
12. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
Jaquet P; Ouafik L; Saveanu A; Gunz G; Fina F; Dufour H; Culler MD; Moreau JP; Enjalbert A
J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698
[TBL] [Abstract][Full Text] [Related]
13. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
[TBL] [Abstract][Full Text] [Related]
14. Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Astrup J; Weeke J; Jørgensen JO
J Clin Endocrinol Metab; 1998 Aug; 83(8):2997-3000. PubMed ID: 9709982
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
Shimon I
Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
[TBL] [Abstract][Full Text] [Related]
18. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
19. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
20. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
